EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou, Maria G; Andreoli, Laura; Limper, Marteen; Amoura, Zahir; Cervera, Ricard; Costedoat-Chalumeau, Nathalie; Cuadrado, Maria Jose; Dörner, Thomas; Ferrer-Oliveras, Raquel; Hambly, Karen; Khamashta, Munther A; King, Judith; Marchiori, Francesca; Meroni, Pier Luigi; Mosca, Marta; Pengo, Vittorio; Raio, Luigi; Ruiz-Irastorza, Guillermo; Shoenfeld, Yehuda; Stojanovich, Ljudmila; ... (2019). EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the rheumatic diseases, 78(10), pp. 1296-1304. BMJ Publishing Group 10.1136/annrheumdis-2019-215213

[img] Text
31092409.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (460kB) | Request a copy

The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS. Risk modification includes screening for and management of cardiovascular and venous thrombosis risk factors, patient education about treatment adherence, and lifestyle counselling. Low-dose aspirin (LDA) is recommended for asymptomatic aPL carriers, patients with systemic lupus erythematosus without prior thrombotic or obstetric APS, and non-pregnant women with a history of obstetric APS only, all with high-risk aPL profiles. Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3. In patients with APS with first arterial thrombosis, treatment with VKA with INR 2-3 or INR 3-4 is recommended, considering the individual's bleeding/thrombosis risk. Rivaroxaban should not be used in patients with APS with triple aPL positivity. For patients with recurrent arterial or venous thrombosis despite adequate treatment, addition of LDA, increase of INR target to 3-4 or switch to low molecular weight heparin may be considered. In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended. In patients with recurrent pregnancy complications, increase of heparin to therapeutic dose, addition of hydroxychloroquine or addition of low-dose prednisolone in the first trimester may be considered. These recommendations aim to guide treatment in adults with APS. High-quality evidence is limited, indicating a need for more research.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Raio, Luigi

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0003-4967

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Monika Zehr

Date Deposited:

27 Dec 2019 09:59

Last Modified:

27 Dec 2019 09:59

Publisher DOI:

10.1136/annrheumdis-2019-215213

PubMed ID:

31092409

Uncontrolled Keywords:

antiphospholipid antibodies antiphospholipid syndrome management pregnancy morbidity recommendations systemic lupus erythematosus thrombosis

BORIS DOI:

10.7892/boris.136550

URI:

https://boris.unibe.ch/id/eprint/136550

Actions (login required)

Edit item Edit item
Provide Feedback